Singapore – Detection of Influenza virus variants
In response to the emergence of Influenza virus variants, and to mitigate any potential risks these may present to our assay performance, Credo Diagnostics conducted the BLASTn analysis (with the oligonucleotide primers and probes of the assays involving Influenza A virus detection) against the sequences of circulating Influenza A(H1N1)pdm09 variants¹ and Influenza A(H3N2) variants (seven variants belong to clade 3C.2a1b.2a.2 and one variant belongs to clade 3C.2a1b.1a) as listed in the Danish published study.²
We are pleased to announce that all our associated Influenza A assays are able to correctly detect these variant strains.
Find out more:
VitaPCR™ Flu A&B assay
VitaPCR™ Flu/RSV assay
VitaPCR™ Influenza/SARS-CoV-2 (Flu/SC2) assay
For more information, contact us at service@credodxbiomed.com.
References:
The Medicines and Healthcare Products Regulatory Agency (MHRA) is aware of an emerging H1N1pdm09 influenza clade (6B.1A.5a.2 and 6B.1A.5a.1) that is circulating in the UK.
Emergence of circulating influenza A H3N2 viruses with genetic drift in the matrix gene: be alert of false-negative test results. APMIS. 2022 Oct;130(10):612-617
